The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Effects of Obesity on Sustained Remission in Early RA

Effects of Obesity on Sustained Remission in Early RA

August 6, 2018 • By Arthritis Care & Research

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Early diagnosis and treatment of rheumatoid arthritis (RA) can minimize progressive joint damage and improve quality of life. But some RA patients still experience suboptimal outcomes, and a better understanding of modifiable factors, such as excess weight, may lead to improved outcomes. In RA patients, obesity has been associated with attenuated treatment response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and other medications. Research has also associated obesity with disease activity measures and lower odds of achieving remission.

You Might Also Like
  • Obesity’s Effects on Inflammatory Markers in Patients with RA
  • Obesity in Women & Smoking in Men Strongly Predict Lack of Remission in Early RA
  • Obesity Linked with Disability in RA

New research from Elizabeth Schulman, MD, and colleagues examined the independent effect of being overweight and obese on a patient’s ability to achieve sustained remission during the first three years after diagnosis. Researchers used data from patients enrolled between January 2007 and November 2014 in the Canadian Early Arthritis Cohort, a multicenter observational trial of early RA patients. During the study, 982 patients were categorized into three body mass index (BMI) groups: healthy BMI (n=315; 32%), overweight (n=343, 35%) and obese (n=324, 33%). Researchers defined sustained remission as a Disease Activity Score in 28 joints (DAS28) of less than 2.6 for two consecutive visits. The results were published in August 2018 Arthritis Care & Research.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Results
“We found that [being] overweight and obesity significantly reduced the likelihood of achieving sustained remission,” write the authors. “Our findings suggest that a BMI [greater than] 25 is a negative prognostic factor associated with persistent disease activity.”

The study found no significant differences in the initial treatment strategies or frequency of methotrexate use across BMI groups. At baseline, 862 patients (88%) were treated with csDMARDs, 27 (3%) with biologics and 93 (9%) with steroids and/or NSAIDs. Treatment with methotrexate was common—739 patients (77%) had received it.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Within the three-year follow-up period, 355 patients (36%) achieved sustained remission. Overweight patients were 25% less likely to achieve sustained remission despite similar initial treatment, with worse outcomes seen in obese patients, of whom 47% failed to achieve sustained remission. In sensitivity analyses, researchers found that obesity was associated with reduced rates of improvement in all four individual component measures of the DAS28. An overweight BMI was primarily associated with reduced rates of improvement in tender joint counts.

Although the mechanisms linking persistent disease activity to excess weight are unclear, it’s also unclear if weight loss will lead to better outcomes.

With obesity rates on the rise, the authors note the importance of these findings for clinicians. They recommend clinicians identify patients at greater risk of persistent disease activity and discuss “data showing a negative impact of adiposity on early RA outcomes. For overweight and obese individuals, facilitating access to weight management programs and other community resources may be helpful for working toward achieving a healthier weight.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Arthritis Care & Research, early RA, Obesity, Remission, Rheumatoid Arthritis (RA)

You Might Also Like:
  • Obesity’s Effects on Inflammatory Markers in Patients with RA
  • Obesity in Women & Smoking in Men Strongly Predict Lack of Remission in Early RA
  • Obesity Linked with Disability in RA
  • Obesity Associated with Increased Inflammatory Markers in Rheumatoid Arthritis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.